JP2010520182A - ヘリコバクターにより引き起こされる感染症の治療のための組成物 - Google Patents
ヘリコバクターにより引き起こされる感染症の治療のための組成物 Download PDFInfo
- Publication number
- JP2010520182A JP2010520182A JP2009551230A JP2009551230A JP2010520182A JP 2010520182 A JP2010520182 A JP 2010520182A JP 2009551230 A JP2009551230 A JP 2009551230A JP 2009551230 A JP2009551230 A JP 2009551230A JP 2010520182 A JP2010520182 A JP 2010520182A
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical composition
- treatment
- helicobacter
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 12
- 241000589989 Helicobacter Species 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 16
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 208000007882 Gastritis Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims 1
- 108010057366 Flavodoxin Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 6
- 239000005516 coenzyme A Substances 0.000 description 6
- 229940093530 coenzyme a Drugs 0.000 description 6
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 4
- 229940013640 flavin mononucleotide Drugs 0.000 description 4
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 4
- 239000011768 flavin mononucleotide Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000023652 chronic gastritis Diseases 0.000 description 3
- 230000027756 respiratory electron transport chain Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101900233525 Helicobacter pylori Flavodoxin Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 0 *[C@@]1C(*=*c2ccccc2)=CC=C(*)[C@]1I Chemical compound *[C@@]1C(*=*c2ccccc2)=CC=C(*)[C@]1I 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- LUAZZOXZPVVGSO-UHFFFAOYSA-N Benzyl viologen Chemical compound C=1C=C(C=2C=C[N+](CC=3C=CC=CC=3)=CC=2)C=C[N+]=1CC1=CC=CC=C1 LUAZZOXZPVVGSO-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100517248 Dictyostelium discoideum nsfA gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 101150091037 nfsB gene Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
【選択図】化1
Description
ヘリコバクターピロリのゲノムDNAはQIAamp DNA Stool Mini Kit(Qiagen)を使用して抗原陽性患者から単離された。
フラボドキシンのためのDNA配列コードは制限酵素Nco(SEQ ID No.1)と、制限酵素BamHI(SEQ ID No.2)とTaq DNAポリメラーゼ(Madgen)を使用してPCRにより増幅された。
増幅後に、600程度のヌクレオチドの破断片が、フラボドキシン遺伝子の破断片(613のヌクレオチド)に対応して検出された。
これら破断片は精製され、標準技術を利用してpET28a(Novagen)発現ベクターのNcol−BamHI部位にクローン化された。遺伝子の注入、その方向性および一体性は、バクテリオファージT7促進物質を使用してプラスミドのDNA配列によって審査された。
E.coli BL21コンピテント細胞が挿入物を含んだpET28aプラスミドで変質あるいはガン化され、カナマイシン(30μg/ml)の存在下、37℃にて10mlのLB培地内において培養された。
ヘリコバクターピロリは、ピルビン酸塩の酸化脱炭酸作用からエネルギーを得るための基本的反応に関与するため、フラボドキシンはヘリコバクターピロリの生存に必須である。この反応では、フラボドキシンはPFOR酵素とFqrB酵素との間で電子を移動させ、電子をNADP+に放出する。
本発明の阻害物質のヘリコバクターピロリのフラボドキシンに対する特異結合は等温適定熱量計(ITC)により確認された。この技術は標的タンパク質に対するそれぞれの化合物の親和性を測定するだけではなく、結合のエンタルピー成分およびエントロピー成分の貢献度をも測定する。
Claims (12)
- R4はアルキル基(C1−C3)であることを特徴とする請求項1記載の化合物。
- R4はメチルであることを特徴とする請求項1または2に記載の化合物。
- R1は窒素であり、R2は酸素であることを特徴とする請求項1から3のいずれかに記載の化合物。
- R5はNO2、COOHまたはSO3Hであることを特徴とする請求項1から4のいずれかに記載の化合物。
- R5はNO2であることを特徴とする請求項1から5のいずれかに記載の化合物。
- nは1であることを特徴とする請求項1から6のいずれかに記載の化合物。
- 感染症の治療のための薬剤組成物を生成するための請求項1から8のいずれかに記載の化合物を含んでいることを特徴とする薬剤組成物。
- 感染症はヘリコバクターによって引き起こされるものであることを特徴とする請求項9記載の薬剤組成物。
- 感染症はヘリコバクターピロリによって引き起こされるものであることを特徴とする請求項9または10に記載の薬剤組成物。
- 感染症は胃炎、胃十二指腸潰瘍、リンパ腫または胃ガンであることを特徴とする請求項9から11のいずれかに記載の薬剤組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200700646 | 2007-03-02 | ||
ES200700646A ES2304221B1 (es) | 2007-03-02 | 2007-03-02 | Composicion para el tratamiento de enfermedades infecciosas causadas por helicobacter. |
PCT/ES2008/000097 WO2008107501A1 (es) | 2007-03-02 | 2008-02-22 | Composition para el tratamiento de enfermedades infecciosas causadas por helicobacter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010520182A true JP2010520182A (ja) | 2010-06-10 |
JP5478264B2 JP5478264B2 (ja) | 2014-04-23 |
Family
ID=39731847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009551230A Expired - Fee Related JP5478264B2 (ja) | 2007-03-02 | 2008-02-22 | ヘリコバクターにより引き起こされる感染症の治療のための組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8367840B2 (ja) |
EP (1) | EP2130824A4 (ja) |
JP (1) | JP5478264B2 (ja) |
ES (1) | ES2304221B1 (ja) |
WO (1) | WO2008107501A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010128156A1 (en) * | 2009-05-08 | 2010-11-11 | Pike Pharma Gmbh | 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication |
WO2015104433A1 (es) * | 2014-01-09 | 2015-07-16 | Universidad De Zaragoza | Derivados de benzo[c][1,2,5]oxadiazol para el tratamiento de enfermedades causadas por helicobater |
ES2796148A1 (es) | 2019-05-21 | 2020-11-25 | Univ Zaragoza | Compuestos para el tratamiento de enfermedades causadas por Helicobacter |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093874A1 (en) * | 2003-04-24 | 2004-11-04 | Universita' Degli Studi Di Roma 'tor Vergata' | Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3394191A (en) * | 1966-02-09 | 1968-07-23 | Monsanto Co | Phenyl beta-nitrostyryl sulfides |
US3629465A (en) * | 1966-08-22 | 1971-12-21 | Givaudan Corp | Preservatives for aqueous systems |
US3985761A (en) * | 1974-10-24 | 1976-10-12 | Sarabhai Research Centre | Nitrothiazolyl derivatives of nitrostyrene |
WO1988003147A1 (en) | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
US5763470A (en) | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
GB9526407D0 (en) | 1995-12-22 | 1996-02-21 | Glaxo Group Ltd | Substances and their uses |
CA2355714A1 (en) | 1998-12-17 | 2000-06-22 | F. Hoffmann-La Roche Ag | 7-aryl-6(z)heptatrienoic acid retinamides as apoptosis inducing compounds and their use as anti-cancer agents |
DE10045599B4 (de) * | 2000-09-15 | 2004-06-03 | Wella Ag | Haarfärbemittel auf der Basis von 4-Nitro-2,1,3-benzoxadiazol-Derivaten und dessen Verwendung als Farbstoff zum Färben von Haaren |
US20040167189A1 (en) * | 2002-03-22 | 2004-08-26 | The Government Of The U.S.A., As Represented By The Secretary, Dept. Of Health And Human Services | Materials and methods for inhibiting Wip1 |
WO2005082341A2 (en) | 2004-02-23 | 2005-09-09 | Prolexys Pharmaceuticals Inc. | NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF |
WO2006002284A1 (en) * | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
-
2007
- 2007-03-02 ES ES200700646A patent/ES2304221B1/es active Active
-
2008
- 2008-02-22 EP EP08750367A patent/EP2130824A4/en not_active Withdrawn
- 2008-02-22 US US12/529,679 patent/US8367840B2/en not_active Expired - Fee Related
- 2008-02-22 WO PCT/ES2008/000097 patent/WO2008107501A1/es active Application Filing
- 2008-02-22 JP JP2009551230A patent/JP5478264B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093874A1 (en) * | 2003-04-24 | 2004-11-04 | Universita' Degli Studi Di Roma 'tor Vergata' | Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy |
Non-Patent Citations (3)
Title |
---|
JPN6013006572; Beteringhe A et al: Internet Electronic Journal of Molecular Design Vol.5, 2006, p.237-46 * |
JPN6013006574; Bem M et al: Revue Roumaine de Chimie Vol.48, 2003, p.387-92 * |
JPN6013006575; 'Belton JG et al' Proceedings of the Royal Irish Academy. Section B:Biolgical, Geological and Chemical Science Vol.74, 1974, p.185-192 * |
Also Published As
Publication number | Publication date |
---|---|
JP5478264B2 (ja) | 2014-04-23 |
EP2130824A1 (en) | 2009-12-09 |
WO2008107501A8 (es) | 2009-10-08 |
WO2008107501A1 (es) | 2008-09-12 |
ES2304221B1 (es) | 2009-09-11 |
US20100063296A1 (en) | 2010-03-11 |
US8367840B2 (en) | 2013-02-05 |
EP2130824A4 (en) | 2010-09-22 |
ES2304221A1 (es) | 2008-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5523841B2 (ja) | 感染症の治療のための組成物 | |
Gobert et al. | Polyamine-and NADPH-dependent generation of ROS during Helicobacter pylori infection: a blessing in disguise | |
Cheng et al. | The PduQ enzyme is an alcohol dehydrogenase used to recycle NAD+ internally within the Pdu microcompartment of Salmonella enterica | |
JP5478264B2 (ja) | ヘリコバクターにより引き起こされる感染症の治療のための組成物 | |
JP5324475B2 (ja) | ヘリコバクターフラボドキシン阻害剤としての化合物の利用 | |
Neujahr et al. | Phenol hydroxylase from yeast: a lysyl residue essential for binding of reduced nicotinamide adenine dinucleotide phosphate | |
Trend et al. | Oxidases and reductases are involved in metronidazole sensitivity in Helicobacter pylori | |
ES2304222B1 (es) | Uso de compuestos para el tratamiento de enfermedades infecciosas causadas por helicobacter pylori. | |
Lu et al. | Roles of cysteine in the structure and metabolic function of Mycobacterium tuberculosis CYP142A1 | |
Ayikpoe | New Insights into Mycofactocin Biosynthesis, Structure and Function | |
US20160298165A1 (en) | Method of treating tuberculosis | |
FR2828207A1 (fr) | Milieux de reaction pour l'activite thymidylate synthase de la thyx | |
Lu | Mechanism and inhibition of bacterial enoyl-ACP reductases: Towards novel antibacterial drugs | |
Villa | Biosynthesis and Use of Cobamides by Prokaryotes | |
Cook et al. | EnergeticsOxidative in Mycobacteria Phosphorylation | |
Picking | Glycine Betaine and Proline Betaine Specific Methyltransferases of the MttB Superfamily | |
Sivaraman | Structure-activity studies of the inhibition of FabI, the enoyl ACP reductase from Escherichia coli by triclosan | |
Quartararo | Enzymes in the persistence phase of Mycobacterium tuberculosis | |
Zhang | Characterisation of bacterial NOS | |
Ma | Cellular iron metabolism and reductase systems in Escherichia coli and Shigella flexneri | |
Ruprecht | The Investigation of Novel Acyl-CoA Dehydrogenases Involved in Bacterial Steroid Degradation | |
Brufau | Exploring novel antibacterial targets and new tools for the study of protein-protein interactions | |
Frederick | Flavin-dependent monooxygenases involved in biosynthetic pathways | |
Croxen | Development of molecular tools to evaluate colonization factors of Helicobacter pylori. | |
Mukhopadhyay | Identification and characterization of genes that protect Escherichia coli from hydrogen peroxide mediated oxidative stress. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140121 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5478264 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |